Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization코로나19 백신 도입 후 유효성 평가: 세계보건기구 잠정지침 요약Article Published on 2021-07-052022-09-11 Journal: Vaccine [Category] SARS, 변종, [키워드] can be used clinical trials conditions COVID-19 COVID-19 vaccine death develop disease dose doses Effectiveness Efficacy eligibility criteria Emergency use Epidemiology evaluate Follow-up Guidance help Immunocompromised Infection intervals outcome pandemic phase platform primary endpoints provided question randomized-controlled recommendation reducing resulting SARS-CoV-2 variant severe disease short duration subpopulations Surveillance symptomatic disease the vaccine Trial vaccination Vaccine vaccine effectiveness Vaccines variants of concern WHO World Health Organization [DOI] 10.1016/j.vaccine.2021.05.099 PMC 바로가기 [Article Type] Article
Epidemiological Study of COVID-19 Fatalities and Vaccine Uptake: Insight From a Public Health Database in Ontario, CanadaAllergy/Immunology Published on 2021-07-042022-10-31 Journal: Cureus [Category] COVID-19, [키워드] addition adjusted age age and gender all age group Canada Case fatality rate CFR CFRs Community COVID 19 COVID-19 COVID-19 mortality death decrease Demographic factors disease distribution Elderly population event exceeded fatality Gender groups highest insight less National occurred Odds ratio per day populations Public reached receiving reported Research responsible rural areas Statistics Canada the vaccine urban area used data vaccination rate Vaccine vaccine science and policy was reduced women [DOI] 10.7759/cureus.16160 PMC 바로가기 [Article Type] Allergy/Immunology
Factors associated with the intention of Syrian adult population to accept COVID19 vaccination: a cross-sectional studyResearch Published on 2021-07-042022-10-28 Journal: BMC Public Health [Category] COVID-19, SARS, [키워드] age approach children conducted coronavirus COVID-19 COVID-19 vaccine COVID19 cross-sectional Demographic factors develop Efficacy Factor Gender global effort increasingly Intention knowledge male overcome pandemic participant Population positive predictor proportion questionnaire required Result severity Side effect smoking Syria the primary endpoint the vaccine vaccinated against COVID-19 vaccination Vaccine Vaccine hesitancy [DOI] 10.1186/s12889-021-11361-z PMC 바로가기 [Article Type] Research
Pre-Vaccination COVID-19 Vaccine Literacy in a Croatian Adult Population: A Cross-Sectional StudyArticle Published on 2021-07-022022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] age alcohol Characteristics Chronic diseases conducted contribute COVID-19 COVID-19 disease COVID-19 pandemic COVID-19 vaccine Croatia cross-sectional effort evaluate functional General population literacy medium pandemic participant professional questionnaire reduced significant difference socio-demographic tested the vaccine translated vaccination vaccination against COVID-19 Vaccine vaccine literacy [DOI] 10.3390/ijerph18137073 PMC 바로가기 [Article Type] Article
Perspectives on vaccine induced thrombotic thrombocytopenia백신 유발성 혈전성 혈소판 감소증에 대한 전망Review Published on 2021-07-012022-09-12 Journal: Journal of autoimmunity [Category] SARS, 진단, [키워드] Activation adverse effect aggregation approach AstraZeneca AstraZeneca vaccine Atypical autoantibody Autoimmune Autoimmune disease bind Brazil bystander catastrophic ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine classical Compound contribute country COVID-19 disease onset disorder disorders France Germany Health heparin-induced thrombocytopenia HIT homological Hypercoagulation Hyperstimulation Hypothesis immune cells Immune-mediated individual infect Manifestations molecular molecular mimicry occur Oxford participant pathogenic autoantibodies Patient PF4 Platelet Randomized controlled trials receptor Safe SARS-CoV-2 sequence South Africa symptomatic the vaccine thrombocytopenia thrombosis thrombotic triggered vaccination Vaccine venous Viral antigen [DOI] 10.1016/j.jaut.2021.102663 PMC 바로가기 [Article Type] Review
Update on geographical variation and distribution of SARS-nCoV-2: A systematic reviewSARS-nCoV-2의 지리적 변이 및 분포에 대한 업데이트: 체계적인 검토Article Published on 2021-07-012022-09-11 Journal: Indian journal of pharmacology [Category] SARS, 변종, 유전자 메커니즘, [키워드] America article Beta Brazil case reports China country COVID-19 database distribution European France Gamma geographical variants Germany globe identify Immunity Iran Ireland Italy mutant mutated Mutation observational studies observational study Region SARS-coronavirus SARS-CoV-2 searched Singapore South Africa Spread strain Strains strains. systematic review the vaccine Transmission variant variants variants of SARS-CoV-2 Variation virulence VoC VOCs VOI [DOI] 10.4103/ijp.ijp_483_21 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial비활성화된 SARS-CoV-2 백신, BBV152의 안전성 및 면역원성: 이중 맹검, 무작위, 다기관, 2상 시험 및 이중 맹검, 무작위 1상 시험의 3개월 추적 조사의 중간 결과Clinical Trial Published on 2021-07-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단, [키워드] 1:1 95% CI Abstract addition Administered Antigen assigned baseline Bharat block blood draw cell-mediated immune response clinical trial collected defined dose double-blind Efficacy elevated elicited enrolled evaluate first dose Follow-up geometric mean GMT healthy high neutralising antibody Hindi hospital humoral inactivated India intramuscular dose investigators Local material microneutralisation test MNT multicentre neutralisation test neutralising antibody titre nine outcomes participant phase 1 trial Phase 2 study phase 2 trial Phase 3 positive Primary outcome PRNT proportion randomisation randomised Randomly reactogenicity receive Registered remained reported response Safety SARS-CoV-2 SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine screened second dose second vaccination secondary outcome selected Serious Adverse Event seroconversion rate serology test significant difference significantly higher Sponsor T-cell Response Th1 phenotype the vaccine titre Toll-like receptor translation treatment group Trial Vaccine was done were assessed were excluded wild-type [DOI] 10.1016/S1473-3099(21)00070-0 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab클라드리빈 또는 오크렐리주맙으로 치료한 다발성 경화증의 코로나19 백신Article Published on 2021-07-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] SARS, 진단, [키워드] antibodies approval COVID-19 COVID-19 vaccine Disease modifying therapy dose Efficacy immune response immunosuppressive drugs Lymphocyte count Multiple multiple sclerosis patients patients treated the timing the vaccine treated Treatment vaccination Vaccine [DOI] 10.1016/j.msard.2021.102983 PMC 바로가기 [Article Type] Article
Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis유지 혈액투석을 받는 환자에서 화이자 BNT162b2 백신에 대한 체액 반응Article Published on 2021-07-012022-09-12 Journal: Clinical journal of the American Society of Nephro [Category] MERS, SARS, 진단, [키워드] 95% confidence interval Abbott acute respiratory syndrome age All participant Antibody Response BNT162 vaccine BNT162b2 BNT162b2 vaccine composed control group controls coronavirus Coronavirus disease 2019 COVID-19 dialysis dose Factor health care workers Hemodialysis humoral IgG IgG level immune response in both groups indicated individual Infection interquartile range inverse correlation knowledge lower quartile lymphocyte Lymphocyte count maintenance Mann-Whitney U test median Medical conditions morbidity and mortality Odds ratio Older Older age Participants Patient Pfizer Pfizer-BioNTech positive reduced renal Renal Dialysis Responder response SARS-CoV-2 second dose serology testing significantly higher significantly lower statistically significant subject the vaccine vaccination Vaccine was done [DOI] 10.2215/CJN.03500321 PMC 바로가기 [Article Type] Article
COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responsesCOVID-19 최적 백신 접종 정책: 효능, 자연 및 백신 유도 면역 반응에 대한 모델링 연구Article Published on 2021-07-012022-09-11 Journal: Mathematical biosciences [Category] 변종, [키워드] accumulate confirmed case country Coverage COVID-19 DALYs death develop dominant dose Efficacy evaluate fraction Health Hospitalization hypothetical identify implication induce Intervention life lockdown Logistic Mask Moderna natural natural immunity new SARS-CoV-2 Optimal control pandemic permanent immunity Pfizer Protective quantified recommendations Reinfection required response responses risk the vaccine vaccination Vaccination policy Vaccine vaccine efficacy Vaccine profile Vaccine-induced immunity variant WHO-SAGE. [DOI] 10.1016/j.mbs.2021.108614 PMC 바로가기 [Article Type] Article